Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-alpha and not by Fas ligand.
暂无分享,去创建一个
L. Moldawer | C. Edwards | E. Copeland | C. Solórzano | C. Tannahill | K. Fukuzuka | F. R. Bahjat | R. Ksontini | C. Tannahill | M. Josephs | S. Mackay | F. Bahjat | S. MacKay
[1] L. Moldawer,et al. Discordant tumor necrosis factor-alpha superfamily gene expression in bacterial peritonitis and endotoxemic shock. , 1999, Surgery.
[2] J. Dhainaut,et al. LPS challenge in D-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock. , 1999, American journal of respiratory and critical care medicine.
[3] B. Haynes,et al. Resistance of CD7-deficient Mice to Lipopolysaccharide-induced Shock Syndromes , 1999, The Journal of experimental medicine.
[4] S. Akira,et al. IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. , 1999, International immunology.
[5] Y. Iwakura,et al. Involvement of Fas/Fas ligand system‐mediated apoptosis in the development of concanavalin A‐induced hepatitis , 1998, European journal of immunology.
[6] G. Nabel,et al. Regulation of the proinflammatory effects of Fas ligand (CD95L). , 1998, Science.
[7] S. Nagata,et al. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand , 1998, Nature Medicine.
[8] K. Iwabuchi,et al. Chemotactic activity of soluble Fas ligand against phagocytes. , 1998, Journal of immunology.
[9] L. Moldawer,et al. Disparate Roles for TNF-α and Fas Ligand in Concanavalin A-Induced Hepatitis , 1998, The Journal of Immunology.
[10] L. Moldawer,et al. Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. , 1998, Journal of applied physiology.
[11] George Kollias,et al. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis , 1997, European journal of immunology.
[12] K. Takeda,et al. Contribution of Fas ligand to T cell-mediated hepatic injury in mice. , 1997, Gastroenterology.
[13] Y. Iwakura,et al. Suppression of concanavalin A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice: role for IFN-gamma in activating apoptosis of hepatocytes. , 1997, Journal of immunology.
[14] L. Moldawer,et al. A MATRIX METALLOPROTEINASE INHIBITOR PREVENTS PROCESSING OF TUMOR NECROSIS FACTOR α (TNFα) AND ABROGATES ENDOTOXIN‐INDUCED LETHALITY , 1997 .
[15] P. M. Davis,et al. Differential Induction of Apoptosis by Fas–Fas Ligand Interactions in Human Monocytes and Macrophages , 1997, The Journal of experimental medicine.
[16] S. Nagata,et al. Essential roles of the Fas ligand in the development of hepatitis , 1997, Nature Medicine.
[17] M. Lambert,et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.
[18] M. Raff,et al. Programmed Cell Death in Animal Development , 1997, Cell.
[19] S. Nagata,et al. Apoptosis by Death Factor , 1997, Cell.
[20] J. Vauthey,et al. Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. , 1997, Journal of immunology.
[21] J. Mountz,et al. Autoimmune disease results from multiple interactive defects in apoptosis induction molecules and signaling pathways. , 1996, Behring Institute Mitteilungen.
[22] M. Leist,et al. DNA fragmentation in mouse organs during endotoxic shock. , 1996, The American journal of pathology.
[23] T. Akaike,et al. Concanavalin A induces perforin‐mediated but not Fas‐mediated hepatic injury , 1996, Hepatology.
[24] P. Kiener,et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils , 1996, The Journal of experimental medicine.
[25] A. H. Drummond,et al. Fas ligand in human serum , 1996, Nature Medicine.
[26] N. Koide,et al. Apoptotic cell death in the response of D-galactosamine-sensitized mice to lipopolysaccharide as an experimental endotoxic shock model , 1996, Infection and immunity.
[27] P. Galle,et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage , 1995, The Journal of experimental medicine.
[28] M. Leist,et al. Tumor necrosis factor-induced hepatic DNA fragmentation as an early marker of T cell-dependent liver injury in mice. , 1995, Gastroenterology.
[29] M. Leist,et al. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. , 1995, The American journal of pathology.
[30] S. Nagata,et al. The Fas death factor , 1995, Science.
[31] M. Leist,et al. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. , 1995, Journal of immunology.
[32] M. Leist,et al. Concanavalin A—induced T‐cell—mediated hepatic injury in mice: The role of tumor necrosis factor , 1995, Hepatology.
[33] S. Nagata,et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes. , 1994, Experimental cell research.
[34] H. Nagai,et al. Mechanism for Macrophage Activation against Corynebacterium parvum—Participation of T Cells and Its Lymphokines , 1994, Microbiology and immunology.
[35] B. Ryffel,et al. Interferon gamma receptor deficient mice are resistant to endotoxic shock , 1994, The Journal of experimental medicine.
[36] V. V. van Hinsbergh,et al. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. , 1993, The Biochemical journal.
[37] R. Zinkernagel,et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes , 1993, Nature.
[38] C. Galanos,et al. Mechanisms of endotoxin shock and endotoxin hypersensitivity. , 1993, Immunobiology.
[39] D. Grobelny,et al. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. , 1992, Biochemistry.
[40] L. Moldawer,et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[41] H. Tabuchi,et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide‐induced lethality , 1991, European journal of immunology.
[42] C. Galanos,et al. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin , 1986, Infection and immunity.
[43] L. Moldawer,et al. Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis. , 1998, Journal of immunology.
[44] L. Moldawer,et al. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. , 1997, Shock.
[45] B. Castner,et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. , 1997, Nature.
[46] H. Yagita,et al. [Metalloproteinase-mediated release of human fas ligand]. , 1996, Nihon rinsho. Japanese journal of clinical medicine.
[47] M. Leist,et al. The 55-kD Tumor Necrosis Factor Receptor and CD95 Independently Signal Murine Hepatocyte Apoptosis and Subsequent Liver Failure , 1996, Molecular medicine.
[48] A. H. Drummond,et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. , 1994, Nature.
[49] S. Nagata,et al. Fas and Fas ligand: a death factor and its receptor. , 1994, Advances in immunology.